The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain

Expert Opinion on Orphan Drugs

Volumn 1, Issue 1, 2013, Pages 77-87

  Niesters, Marieke ^a   Swartjes, Maarten ^a   Heij, Lara ^a   Brines, Michael ^b   Cerami, Anthony ^a,b   Dunne, Ann ^b   HoitsM A , Elske ^c   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ARAIM PHARMACEUTICALS   (United States)

^c Department of Neurology ^*  (Netherlands)

Author keywords

Anti inflammation; ARA 290; Chronic pain; Innate repair receptor; Neuropathic pain; Pain; Sarcoidosis

Indexed keywords

ARA 290; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NITRIC OXIDE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLODYNIA; AMINO ACID SEQUENCE; ANALGESIA; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLUNT TRAUMA; CARDIOMYOPATHY; CHEMISTRY; CHRONIC PAIN; CLINICAL FEATURE; COUGHING; CRUSH TRAUMA; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA NODOSUM; ERYTHROPOIESIS; ETHNICITY; FATIGUE; FEVER; GLIA CELL; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; LUNG FIBROSIS; MOLECULAR WEIGHT; MORTALITY; MOTOR PERFORMANCE; NEUROPATHIC PAIN; NIGHT SWEAT; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVE INJURY; PHARMACOKINETICS; PLASMA HALF LIFE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOIDOSIS; SARCOIDOSIS INDUCED CHRONIC NEUROPATHIC PAIN; SCIATIC NERVE; SMALL FIBER NEUROPATHY; SPINAL CORD COMPRESSION; SPINAL NERVE; THROMBOSIS; TISSUE INJURY; TREATMENT DURATION; WEIGHT REDUCTION; WOUND HEALING;

EID: 84896692217     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.719289     Document Type: Article

References (47)

1. Baron R, Binder A, Wasner G. Neuropathic pain. Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19
2. Hoitsma E. Small fiber neuropathy: a novel finding in sarcoidosis. PhD thesis, University of Maastricht; 2005
3. Tavee J, Culver S. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011;15:201-6
4. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
5. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
6. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105:10925-30
7. Ahmet I, Tae HJ, Juhaszova M, et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011;17:194-200
8. Polgarova K, Luthje P, Cerami A, Brauner A. The erythropoietin analogue ARA 290 modulates the innate response and reduces Escherichia coli invasion into urothelial cells. FEMS Immunol Med Microbiol 2011;62:190-6
9. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. New Engl J Med 2007;357:2153-65
10. Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001;18(Suppl 32):56s-68s
11. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007;131:1414-23
12. Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359(9323):2085-6
13. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis. Respir Med 2011;105:95-100
14. Hoitsma E, Faber CG, van Kroonenburgh MJ, et al. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:43-50
15. Hoitsma E, Reulen JP, De BM, et al. Small fiber neuropathy: a common and important clinical disorder. J Neurol Sci 2004;227:119-30
16. Burns TM, Dyck PJB, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 limb sracoidosis neuropathy cases. J Neurol Sci 2006;244:77-87
17. Baughmann RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis ands its potential for targeted therapy. BioDrugs 2003;17:425-31
18. Baughmann RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
19. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:73-7
20. Cerami A. TNF and EPO: major players in the innate immune response: their discovery. Ann Rheum Dis 2012;71(Supp II):i55-9
21. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med 2012;18:486-96
22. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12
23. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Int Med 2008;262:405-32
24. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10536-1
25. Grasso G, Graziano F, Sfacteria A, et al. Neuroprotective effect of erythropoietin and darbepoietin alfa after experimental intracerebral hemorrhage. Neurosurg 2009;65:763-9
26. Liao ZB, Zhi XG, Shi QH, He ZH. Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol 2008;15:140-9
27. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoietin alfa in critically ill patients. N Engl J Med 2007;357:965-76
28. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
29. Erbayraktar Z, Erbayraktar S, Yilmaz O, et al. Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 2009;15:235-41
30. Swartjes M, Morariu A, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice. Anesthesiology 2011;115:1084-92
31. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-8
32. Campana WM, Li X, Shubayev VI, et al. Erythropoietin reduces schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 2006;23:617-26
33. Suter MR, Papaloizos M, Berde CB, et al. Development of neuropathis pain in the rat spared nerve injury model is not prevented by a peripheral nerve block. Anesthesiology 2003;99:1402-8
34. Tanga FY, Raghavendra V, DeLeo JA. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int 2004;45:397-407
35. Empl M, Renaud S, Erne B, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001;56:1371-7
36. Homma Y, Brull SJ, Zhang JM. A comparison of chronic pain behavior following local application of tumor necrosis factor [alpha] to the normal and mechanically compressed lumbar ganglia in the rat. Pain 2002;95:239-46
37. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, et al. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004;45:89-95
38. Zhang L, Berta T, Xu ZZ, et al. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 2011;152:419-27
39. Jia H, Feng X, Li W, et al. Recombinant human erythropoietin attenuates spinal neuroimmune activation of neuropathic pain in rats. Ann Clin Lab Sci 2009;39:84-91
40. Jia H, Jin Y, Ji Q, et al. Effects of recombinant erythropoietin on neuropathic pain and cerebral expressions of cytokines and nuclear factor-kappa B. Can J Anesth 2009;56:597-603
41. Dahan A, Olofsen E, Sigtermans M, et al. Population pharmacokineticpharmacodynamic modeling of ketamine-induced pain relief of chronic pain. Eur J Pain 2011;15:258-67
42. Dahan A, Heij L, Niesters M, et al. Safety and efficacy of ARA 290 in neuropathy associated with sarcoidosis: a pilot study. In preparation
43. Burgess G, Williams D. The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest 2010;120:3753-9
44. Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-66
45. Woolf CJ. What is this thing called pain? J Clin Invest 2010;120:3742-4
46. Noppers I, Niesters M, Aarts L, et al. Ketamine for treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010;11:2417-29
47. Sigtermans M, van Hilten JJ, Bauer MCR, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain 2009;145:304-11